18F-fluoride PET as a non-invasive imaging biomarker for determining treatment efficacy of bone active agents at the hip: A prospective, randomised, controlled clinical study

Journal of Bone and Mineral Research, 02/22/2013

The aim of this study was to determine if 18F–PET can be used as an early biomarker of treatment efficacy at the hip. Changes in BMD and bone turnover markers were consistent with previous trials of teriparatide. In conclusion, this is the first study demonstrating that 18F–PET can be used as an imaging biomarker for determining treatment efficacy at the hip as early as 12–weeks following initiation of therapy.

Print Article Summary